C14ORF169在结直肠癌中的表达及对化疗和预后的影响

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (84836 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To explore the expression of C14ORF169 in patients with colorectal cancer, and analyze its impact on efficacy of chemotherapy and prognosis. Methods:C14ORF169 differences in expression level of colorectal adenoma, colorectal cancer and corresponding normal tissues were compared using Oncomine database. The correlation of C14ORF169 expression with patients′clinicopathological characteristics and prognosis was analyzed by using the GSE12945 and GSE17536 colorectal cancer datasets downloaded from the gene expression omnibus （GEO） database. The C14ORF169 over expression and knockdown colorectal cancer cell lines were constructed respectively, and the 5-fluorouracil （5-FU） halfmaximal inhibitory concentration （IC50） was detected by using CCK-8 method. Results: The level of C14ORF169 in colorectal adenomas and colorectal cancer tissues were significantly higher than that in normal tissues （P<0.05）. Overall survival and colorectal cancer specific survival of patients with high expression of C14ORF169 were significantly shorter than those with low C14ORF169 expression （P<0.05）. High expression of C14ORF169 was closely related to AJCC advanced stage of colorectal cancer. The sensitivity of colorectal cancer cells to 5FU increased after C14ORF169 knockdown, while C14ORF169 overexpression cell lines showed enhanced chemoresistance. Conclusion: C14ORF169 is highly expressed in colorectal cancer, which is associated with chemotherapy resistance and poor prognosis.

Received: 24 December 2020

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LUO Tingyi
	SUN Wei
	YANG Tingsong
	WANG Shilin
	HUO Yuhu
	WEI Haihong
	XU Bin

Cite this article:

LUO Tingyi,SUN Wei,YANG Tingsong等.

Expression of C14ORF169 in colorectal cancer and its effect on chemotherapy and prognosis

[J]. Journal of Jiangsu University(Medicine Edition), 2021, 31(04): 284-289.

URL:

http://zzs.ujs.edu.cn/xbyxb/EN/ OR http://zzs.ujs.edu.cn/xbyxb/EN/Y2021/V31/I04/284

［1］Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］. CA Cancer J Clin, 2020, 70（4）: 313.

［2］Arnold M, Sierra MS, Laversanne M, et al. Global patterns and trends in colorectal cancer incidence and mortality［J］. Gut, 2017, 66（4）: 683-691.

［3］Chen WQ, Zheng RS, Baade PD, et al. Cancer Statistics in China, 2015［J］. CA Cancer J Clin, 2016, 66（2）: 115-132.

［4］Tan E, Gouvas N, Nicholls RJ, et al. Diagnostic precision of carcinoembryonic antigen in the detection of recurrence of colorectal cancer［J］. Surg Oncol, 2009, 18（1）: 15-24.

［5］Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018［J］. CA Cancer J Clin, 2018, 68（1）: 7-30.

［6］Choi JE, Bae JS, Kang MJ, et al. Expression of epithelialmesenchymal transition and cancer stem cell markers in colorectal adenocarcinoma: clinicopathological significance［J］. Oncol Rep, 2017, 38（3）: 1695-1705.

［7］Eilbracht J, Reichenzeller M, Hergt M, et al. NO66, a highly conserved dual location protein in the nucleolus and in a special type of synchronously replicating chromatin［J］. Mol Biol Cell, 2004, 15（4）: 1816-1832.

［8］Brien GL, Gambero G, O′Connell DJ, et al. Polycomb PHF19 binds H3K36me3 and recruits PRC2 and demethylase NO66 to embryonic stem cell genes during differentiation［J］. Nat Struct Mol Biol, 2012, 19（12）: 1273-1281.

［9］Ougolkov AV, Bilim VN, Billadeau DD. Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2［J］. Clin Cancer Res, 2008, 14（21）: 6790-6796.

［10］Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation［J］. Cell, 2011, 144（5）: 646-674.

［11］Baba Y, Murata A, Watanabe M, et al. Clinical implications of the LINE1 methylation levels in patients with gastrointestinal cancer［J］. Surg Today, 2014, 44（10）: 1807-1816.

［12］Suzuki C, Takahashi K, Hayama S, et al. Identification of Mycassociated protein with JmjC domain as a novel therapeutic target oncogene for lung cancer［J］. Mol Cancer Ther, 2007, 6（2）: 542-551.

［13］PiresLuis AS, VieiraCoimbra M, Vieira FQ, et al. Expression of histone methyltransferases as novel biomarkers for renal cell tumor diagnosis and prognostication［J］. Epigenetics, 2015, 10（11）: 1033-1043.

［14］Sinha KM, BagheriYarmand R, Lahiri S, et al. Oncogenic and osteolytic functions of histone demethylase NO66 in castrationresistant prostate cancer［J］. Oncogene, 2019, 38（25）: 5038-5049.

［15］Wang Q, Liu PY, Liu T, et al. The histone demethylase NO66 induces glioma cell proliferation［J］. Anticancer Res, 2019, 39（11）: 6007-6014.

［16］Nishizawa Y, Nishida N, Konno M, et al. Clinical significance of histone demethylase NO66 in invasive colorectal cancer［J］. Ann Surg Oncol, 2017, 24（3）: 841-849.

［17］Camp RL, DolledFilhart M, Rimm DL. Xtile: a new bioinformatics tool for biomarker assessment and outcomebased cutpoint optimization［J］. Clin Cancer Res, 2004, 10（21）: 7252-7259.

［18］SabatesBellver J, Van der Flier LG, de Palo M, et al. Transcriptome profile of human colorectal adenomas［J］. Mol Cancer Res, 2007, 5（12）: 1263-1275.

［19］Skrzypczak M, Goryca K, Rubel T, et al. Modeling oncogenic signaling in colon tumors by multidirectional analyses of microarray data directed for maximization of analytical reliability［J］. PLoS One, 2010, 5（10）: e13091.

［20］Resch A, Langner C. Lymph node staging in colorectal cancer: old controversies and recent advances［J］. World J Gastroenterol, 2013, 19（46）: 8515-8526.

［21］Stewart CL, Warner S, Ito K, et al. Cytoreduction for colorectal metastases: liver, lung, peritoneum, lymph nodes, bone, brain. When does it palliate, prolong survival, and potentially cure?［J］. Curr Probl Surg, 2018, 55（9）: 330-379.

［22］Woo IS, Jung YH. Metronomic chemotherapy in metastatic colorectal cancer［J］. Cancer Lett, 2017, 400: 319-324.

［23］Fan CW, Chen T, Shang YN, et al. Cancerinitiating cells derived from human rectal adenocarcinoma tissues carry mesenchymal phenotypes and resist drug therapies［J］. Cell Death Dis, 2013, 4: e828.

［24］Yaffee P, Osipov A, Tan C, et al. Review of systemic therapies for locally advanced and metastatic rectal cancer［J］. J Gastrointest Oncol, 2015, 6（2）: 185-200.